AdvaMed Distances Devices From Proposed Postmarket Surveillance Reforms
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed is continuing to draw attention to essential differences between medical device and drug postmarket regulation as FDA faces increased public scrutiny related to drug recalls